# OnCo record nct03459170 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03459170/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03459170", "NCT03459170" ;
  schema:name "Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant"@en ;
  schema:description "A phase 1 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03459170/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03459170> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/rivogenlecleucel/> ;
  onco:companies <https://onco.cc/companies/bellicum/> .